PALA versus streptozotocin, doxorubicin, and MeCCNU in the treatment of patients with advanced pancreatic carcinoma

Investigational New Drugs

Volumn 16, Issue 4, 1998, Pages 315-318

  Witte, Robert S ^a   Ryan, Louise M ^b   Schutt, Allan J ^c   Carbone, Paul P ^d   Engstrom, Paul F ^e  

^a GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

^e FOX CHASE CANCER CENTER   (United States)

Author keywords

Doxorubicin; MeCCNU; PALA; Pancreatic carcinoma; Streptozotocin

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; SEMUSTINE; SPARFOSIC ACID; STREPTOZOCIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LIFE EXPECTANCY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PANCREAS CARCINOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SEPSIS; SKIN TOXICITY; TREATMENT FAILURE; UROGENITAL TRACT DISEASE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTIC ACID; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PHOSPHONOACETIC ACID; SEMUSTINE; STREPTOZOCIN; SURVIVAL ANALYSIS;

EID: 0032456595     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006292218890     Document Type: Article

References (20)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1998. Cancer J Clin 48: 6-29, 1998
2. Carter SK: The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev 3: 193, 1975
3. Manheimer LH, Vital J: Mitomycin C in the therapy of far-advanced malignant tumors. Cancer 19: 207-212, 1966
4. duPriest RW Jr, Huntington MC, Massey WH, Weiss AJ, Wilson WL, Fletcher WS: Streptozotocin therapy in 22 cancer patients. Cancer 35: 358-367, 1975
5. Wasserman TH, Slavic M, Carter SK: Methyl CCNU in Clinical Cancer Therapy. Cancer Treatment Reviews 1: 251, 1974
6. Schein PS, Lavin PT, Moertel CG et al.: Randomized phase II clinical trial of adriamycin, methotrexate and actinomycin D in advanced measurable pancreatic carcinoma. Cancer 42: 19-22, 1978
7. Bukowski RM, Schacter LP, Groppe CW, Hewlett JS, Weick JK, Livingstone RB: Phase II Trial of 5-Fluorouracil, Adriamycin, Mitomycin C, and Streptozotocin (FAM-S) in Pancreatic Carcinoma. Cancer 50: 197-200, 1982
8. Smith FP, Hoth DF, Levin BL et al.: 4-Fluorouracil, adriamycin and mitomycin and mitomycin C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 46: 2014-2018, 1980
9. Oster MW, Gray R, Panasci L et al.: Chemotherapy for advanced pancreatic cancer: a comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, Streptozotocin, and mitomycin (FSM). Cancer 57: 29, 1986
10. Gastrointestinal Tumor Study Group: Phase II studies of drug combinations in advanced pancreatic carcinoma; fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. J Clin Oncol 4: 1794, 1986
11. Cullinan SA, Moertel CG, Fleming TR et al.: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 253: 2061, 1985
12. Collins KD, Start GR: Aspartate Transcarbamylase. Interaction with the transition state analog N-(Phosphonacetyl)-L-aspartate. J Biol Chem 246: 6566-6605, 1971
13. Yoshida T, Stark GR, Hoogenraad NJ: Inhibition of N-(Phosphonacetyl)-L-aspartate of Aspartate Transcarbamylase Activity and Drug-Induced Cell Proliferation in Mice. J Biol Chem 249: 6951-6955, 1974
14. Johnson RK, Inouye T, Goldin A, Start GR: Anti-tumor activity of N-(Phosphonacetyl)-L-aspartate Acid, A transition-state inhibitor of Aspartate Transcarbamylase. Cancer Res 36: 2720-2725, 1976
15. Clinical Brochure, PALA (NSC 224131), National Cancer Institute, December, 1977
16. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
18. Abbruzzese JL, Grunewald R, Weeks EA et al.: A phase I clinical plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 9: 491-498, 1991
19. Casper ES, Green MR, Kelsen DP et al.: Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with ad-enocarcinoma of the pancreas. Invest New Drugs 12: 29, 1994
20. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997